MIT-A and DHM are vendor-side labels for products containing MGM-15 (dihydro-7-hydroxymitragynine), usually blended with concentrated mitragynine. The labels don’t point at different chemistry. Every commercial product carrying either name that’s been characterized in the published literature has come back as MGM-15.
The “DHM” label borrows from the technical name (dihydro-7-hydroxymitragynine) while obscuring that the named compound is reduced from 7-OH, not from mitragynine — there is no clean, characterized “dihydro-mitragynine” in any of these products. “MIT-A” is marketed as “Mitragynine plus Advanced Alkaloids” or close variants, with the “Advanced Alkaloids” framing telling the reader nothing about what’s actually in the product. In the products that have been tested, that unnamed alkaloid content includes MGM-15.
The full picture — chemistry of how MGM-15 is made (and why “reducing mitragynine” wouldn’t give a clean product), the GC-MS testing problem that lets vendors publish “no 7-OH” COAs on products containing it, the regulatory gap that created the market, the dose patterns, the longer-and-harder withdrawal pattern, and the Suboxone / SR-17 paths for coming off — lives on /compounds/mgm15.
An earlier version of this page treated MIT-A and DHM as a distinct compound category. That framing was wrong on the underlying chemistry. The corrected picture is on the MGM-15 page.